antagonist; antidiabetic and antiobesity agent. Attenuates troglitazone-induced PPARγ
transcriptional activity (IC50
= 140 μ
M) without affecting ligand-stimulated PPARα
or FXR transcriptional activity. Inhibits PPARγ
-dependent adipocyte differentiation and growth in vitro
and in vivo
. Improves insulin sensitivity in diabetic ob/ob mice and increases HDL levels in rats in vivo
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
gem-Diphosphonate and gem-phosphonate-phosphate compounds with specific high density lipoprotein inducing activity.
Nguyen et al.
A new selective peroxisome proliferator-activated receptor γ antagonist with antiobesity and antidiabetic activity.
Rieusset et al.
Do peroxisome proliferation receptor-γ antagonists have clinical potential as combined antiobesity and antidiabetic drugs?